Gene Editing Advances: A 2026 Roundup

A series of studies published in early 2026 describe new developments in gene editing technology, including methods to improve the delivery of editing tools, insert larger DNA sequences, and target tumor cells based on epigenetic markers. The research addresses different challenges in gene therapy, from production efficiency to cell-specific targeting.

Advances in Virus-Like Particle Production

Study Overview

Researchers at the Whitehead Institute developed a platform to screen human genes in "producer" cells—cells used to manufacture delivery vehicles—for factors affecting the assembly of virus-like particles (VLPs) used for gene therapy delivery. The study was published in Nature Communications on April 24, 2026, and was led by Aditya Raguram and Diana Ly.

Findings

The platform involved individually switching off each gene in a pool of producer cells and tracking the effect on VLP production.

Disabling a gene that normally limits guide RNA output resulted in increased VLP production. The resulting engineered cells produced more guide RNA molecules and functional cargo per particle. This improvement was observed with multiple gene editors and four different VLP designs from other laboratories.

A second set of genes, when removed, increased protein components in the particles but reduced delivery potency. In experimental contexts where protein cargo is scarce, potency was increased.

Next Steps

The Raguram Lab is extending the platform to study cellular changes beyond single-gene shutdowns. They are sharing engineered cell lines and collaborating with other researchers to improve delivery into immune cells, neurons, and other cell types. The stated long-term goal is to use these particles for treating genetic diseases.

Method for Large DNA Insertion

Study Overview

Researchers described a gene-editing technique called "prime assembly" capable of inserting up to 11,000 base pairs of DNA into a genome. The method builds on existing prime editing technology and uses overlapping DNA flaps to attach donor DNA. The study was published in Nature on April 29, 2026.

Method

Prime assembly uses twin prime editing to create flaps on target DNA that complement the ends of donor DNA. This process induces only a single-strand DNA break. The method does not rely on homology-directed repair, which has been reported as inefficient in animal models.

Applications

The technique can be applied to non-dividing cells, including neurons and heart cells. Bin Liu, co-lead author and assistant professor at the Ohio State University College of Medicine, stated that the method allows for the correction of "1,000 heterogeneous mutations at once." The study involved mammalian cells.

Background

The work was co-led by Erik Sontheimer and Wen Xue at UMass Chan Medical School. Funding was provided by the National Institutes of Health (NIH), the Leducq Foundation, and the Cystic Fibrosis Foundation. Further work includes determining the optimal delivery vehicle (lipid nanoparticle or adeno-associated virus) and testing in living organisms.

DNA-Guided CRISPR System

Study Overview

Engineers at the University of Florida developed a CRISPR system that uses DNA, rather than RNA, as a guide to target RNA molecules. The work was first reported in a 2024 preprint and formally published in Nature Biotechnology.

System Characteristics

The system uses DNA guides, which are more stable and easier to produce than RNA guides. It targets RNA, allowing intervention without altering DNA directly. Researchers reported reduced off-target effects and lower manufacturing costs. The system can detect viruses including HIV and hepatitis C.

Lead Researcher Statement

Piyush Jain, associate professor and lead author, stated that the approach allows for "fixing or tuning instructions the cell is using in real time, without immediately changing the DNA."

Development Timeline

Jain estimated that early targeted applications could emerge within a few years, particularly in ex vivo treatments. Broader clinical use will require additional testing and regulatory approval.

Engineered Smaller CRISPR Nuclease Variant

Study Overview

A research team from the University of Texas at Austin, in partnership with Metagenomi Therapeutics and funded by the NIH, developed a modified version of a bacterial nuclease enzyme for gene editing. The study was published in Nature Structural & Molecular Biology.

Enzyme Characteristics

The enzyme, Al3Cas12f, is a naturally occurring bacterial nuclease. The team created an engineered variant named Al3Cas12f RKK. Analysis using cryo-electron microscopy and machine learning indicated that Al3Cas12f has an expanded interface between its components, contributing to its structural stability.

Background

Clinical applications of CRISPR-based gene editing have largely been limited to editing cells outside the body (ex vivo). A primary limitation is that many effective gene-editing tools exceed the packaging capacity of adeno-associated virus (AAV) vectors, which have a limit of approximately 1,000 amino acids. Smaller nucleases from the Cas12f group (400-700 amino acids) have been explored but previously showed limited effectiveness in human cells.

Research Findings

The original Al3Cas12f enzyme demonstrated editing efficiency surpassing two other Cas12f enzymes recently used in mouse studies. The engineered RKK variant was tested in a line of human cells originally isolated from a patient with leukemia. Genes targeted for editing were associated with diseases including cancer, atherosclerosis, and amyotrophic lateral sclerosis (ALS). The RKK variant improved editing efficiency from less than 10% to more than 80% across the tested targets.

Statements and Next Steps

David Taylor, a UT molecular biosciences professor and study co-author, stated that understanding the enzyme's features allows for rational design of improved variants that maintain a compact size suitable for delivery. Researchers plan to test the nuclease's performance when packaged into AAV vectors.

Erica Brown, Ph.D., acting director of the NIH's National Institute of General Medical Sciences (NIGMS), described the finding as "a significant step" toward smart delivery of gene-editing systems.

AI-Enhanced Safety in Gene Editing

Study Overview

A team led by Associate Professor Gavin Knott from Monash University utilized artificial intelligence to address the risk of unintended damage to healthy genes during gene editing. The discovery was published in the journal Nature Chemical Biology.

Development

The team developed a method to prevent the active enzyme in gene editing from lingering and causing unintended damage. The innovation is currently in development in a laboratory setting.

Statement

Associate Professor Kate Michie, a molecular biologist from the University of New South Wales not involved in the research, described the finding as "really significant," stating that it proves protein design is possible and addresses what she called a "holy grail problem of biology."

CRISPR Variant for Selective Tumor DNA Targeting

Study Overview

A research team from Wageningen University & Research and Van Andel Institute published a study in Nature on April 15, 2026, describing the use of a CRISPR variant called ThermoCas9 to distinguish between tumor DNA and healthy DNA. The method relies on differences in DNA methylation patterns.

Mechanism

ThermoCas9 is a CRISPR-associated enzyme discovered in bacteria by John van der Oost of Wageningen University. The enzyme binds to a specific recognition sequence called a PAM (Protospacer Adjacent Motif). The PAM sequence for ThermoCas9 includes a site where human DNA methylation can occur. When a methyl group is present at this site, it disrupts ThermoCas9's binding to the DNA, preventing cleavage. In cells with aberrant methylation patterns—as observed in the tested tumor cells—ThermoCas9 can bind and cut the DNA.

Research Status

In laboratory experiments using human cells grown in culture dishes, ThermoCas9 selectively cut DNA in tumor cells while leaving DNA in healthy cells intact. The study represents the first reported instance of a CRISPR-based method using DNA methylation to target human cancer cells.

The study demonstrated selective DNA cleavage but did not show that this effect can kill tumor cells. Researchers stated the next step is to investigate whether damaging tumor DNA with this method can trigger cell death. The technology is not yet ready for clinical use as a cancer treatment.

Broader Applications

The researchers noted that aberrant methylation patterns are involved in other diseases, including neuroblastoma and autoimmune disorders, suggesting potential broader applications for this approach.

Statements

John van der Oost stated: "ThermoCas9 is the first CRISPR-associated enzyme to respond to differences in the most abundant type of DNA methylation in human and other eukaryotic cells. This means we now have a system that we can target specifically toward tumor cells."

Hong Li of Van Andel Institute stated: "ThermoCas9 uses methylation like an address to precisely target cancer cells while leaving healthy cells untouched."

Funding and Authorship

The research was supported by multiple grants from the NIH, the Dutch Research Council, the European Research Council, the University Fund Wageningen, and the Dutch Ministry of Economic Affairs. Co-first authors include Mitchell O. Roth, Yuerong Shu, Yu Zhao, Renee D. Hoffman (Van Andel Institute), and Despoina Trasanidou (Wageningen University).